Carbonell-Estrany et al.: Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial
Carbonell-Estrany, X; SimÃµes, EA; Dagan, R; Hall, CB; Harris, B; Hultquist, M; Connor, EM; Losonsky, GA; Motavizumab Study Group.
Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
Pediatrics. 2010; 125(1): e35-e51. [Fulltext] [PubMed]
- OBJECTIVE: Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab. METHODS: This randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged